SecBot SecBot

RARE

Ultragenyx Pharmaceutical Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001515673 Biotech & Drug Discovery
$15.90 −0.18 (−1.12%)
Nov 16 4:00 PM ET · prev $16.08
Market cap
$1.7B
Small cap
Consensus
Buy
59% Buy or better · 27 analysts
Median target
🔒 Subscribers only
1 year
−51.1%
from $32.54 · Nov 17
30 days
+5.5%
from $15.07
52-week range
$12.88–36.54
−56% from high · low Sep 16
Avg volume 20D
3.64M
shares / day
Short interest
23.62M
≈23.2% of shares · +17.3%
Days to cover
8.3
at average volume
Insider net
−$3.0M
0 buyers · 8 sellers · since Mar 2
New fund stakes
4
Q3 2026 13F · 5 exits
Reddit crowd
58°
Warm · 2 mentions this week
SecBot read MIXED 12 reports · 90 days
Balance 2 bearish · 4 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 12/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    8 insiders sold $3.0M.

  • InstitutionsMIXED

    Q3 2026: 38 added (4 new), 32 trimmed or exited. Largest new: Hrt Financial $11.9M, Jane Street Group $10.5M.

  • AnalystsBULLISH

    16 of 27 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.929 → $0.655 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +17.3% to 23.62M shares. 8.3 days to cover, ≈23.2% of shares.

  • TrendUPTREND

    4% above its 50-day average.

  • SocialQUIET

    Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
4
new positions
5
exits
$22.4M
in new stakes · top 2 shown
FundMoveSharesValue
Qube Research & Technologies LtdADD1,345,150$20.2M
Jefferies Financial Group Inc.ADD1,339,814$20.1M
HRT FINANCIAL LPNEW794,358$11.9M
PANAGORA ASSET MANAGEMENT INCADD776,473$11.7M
RAYMOND JAMES FINANCIAL INCDOUBLED766,532$11.5M
CITIGROUP INCDOUBLED766,024$11.5M
MORGAN STANLEYTRIM749,194$11.3M
Jump Financial, LLCDOUBLED704,752$10.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 59% rate it Buy or better
Strong Buy6Buy10Hold11Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 5, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 4, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 4, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 4, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 4, 2026Goldman Sachs
MAINTAIN
MAINTAINNeutral

Washington

Corporate Lobbying

33 lobbying filings and 3 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$3.0M
sold · 8 insiders
DateInsiderTypeValue
Oct 15, 2026
Horn Howard
Chief Financial Officer
Oct 15, 2026
SELL$107.9K
Sep 15, 2026
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Sep 15, 2026
SELL$17.4K
Sep 3, 2026
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Sep 3, 2026
SELL$2.3K
Aug 3, 2026
Parschauer Karah Herdman
EVP and Chief Legal Officer
Aug 3, 2026
SELL$47.3K
Aug 3, 2026
Horn Howard
Chief Financial Officer
Aug 3, 2026
SELL$117.0K
Jul 1, 2026
Horn Howard
Chief Financial Officer
Jul 1, 2026
SELL$155.6K
Jun 15, 2026
Sanders Corazon (Corsee) D.
Director
Jun 15, 2026
SELL$50.1K
Jun 15, 2026
Parschauer Karah Herdman
EVP and Chief Legal Officer
Jun 15, 2026
SELL$46.8K

Earnings setup

Estimates
$0.66
EPS estimate, this quarter
+171%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.66-$1.04–$2.46+215.1%$234.1M
Next Q-$0.04-$0.45–$0.63+90.9%$198.7M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 11, 2026
Press release
Ultragenyx to Participate at Investor Conferences in London
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the…
Nov 6, 2026
Press release
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and…
Nov 3, 2026
Earnings
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million
Nov 3, 2026
Earnings result
RARE Q3 2026 Earnings: EPS $-1.16 (-1.8% vs est)
Nov 3, 2026
Clinical Trial
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
Phase 2 · TERMINATED

Short side

FINRA· Oct 30, 2026
23,624,682
shares short
+17.3%
vs prior settlement
8.3
days to cover
≈23.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
AQR Capital Management filed an amended Schedule 13G disclosing a 0.64% passive stake in Ultragenyx Pharmaceutical as…
SC 13G/A · Impact 2/10
Nov 11, 2026 Other
Ultragenyx to Participate at Investor Conferences in London
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a b
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a 7.6% passive stake in Ultragenyx Pharmaceutical as of…
SC 13G · Impact 3/10
Nov 3, 2026 SEC
Ultragenyx completed the sale of a Rare Pediatric Disease PRV for $210M in gross proceeds (net ~$168M after NIH…
8-K · Impact 6/10
Oct 28, 2026 Event
HSR Early Termination: C.H. Boehringer Sohn AG & Co. KG; Ultragenyx Pharmaceutical Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving C.H. Boe
Oct 15, 2026 Insider
Horn Howard sold 7,066 shares
Chief Financial Officer @ $15.27 ($107.9K)
Sep 30, 2026 Inst.
Qube Research & Technologies · ADD
1,345,150 shares ($20.2M)
Sep 30, 2026 Inst.
Jefferies Financial Group Inc. · ADD
1,339,814 shares ($20.1M)
Reddit Mentions per day, 14 days
Crowd this week 58° Warm 1 bullish · 0 bearish
Mentions, 7 days 2 0 in posts · 2 in comments
Recent posts
Recent comments
All social signals and their track records
Congressional trades
RARE trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
DateMemberType AmountDisclosed
Sep 29, 2026 Gilbert CisnerosDHouse Ultragenyx Pharmaceutical Inc BUY $1K–$15K Oct 12, 2026 +13d
Mar 3, 2026 Gilbert CisnerosDHouse Ultragenyx Pharmaceutical Inc BUY $1K–$15K Apr 7, 2026 +35d

SecBot reports

20 filings · 2 press releases · 4 bullish · 4 bearish · 1 mixed · 11 neutral
All RARE filing & press-release reports (22)